Scarica l'app Stockscreener
28.75
1.45%
0.41
Dopo l'orario di chiusura:
28.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.34
Aprire:
$28.33
Volume 24 ore:
244.65K
Relative Volume:
2.04
Capitalizzazione di mercato:
$456.91M
Reddito:
$71.10M
Utile/perdita netta:
$-6.38M
Rapporto P/E:
-23.94
EPS:
-1.2009
Flusso di cassa netto:
$-39.84M
1 W Prestazione:
+8.41%
1M Prestazione:
+3.16%
6M Prestazione:
-22.69%
1 anno Prestazione:
+112.65%
Intervallo 1D:
$27.41
$29.05
Intervallo di 1 settimana:
$25.76
$31.89
Portata 52W:
$13.70
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Nome
Assembly Biosciences Inc
Settore
Industria
Telefono
(833) 409-4583
Indirizzo
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
28.75 | 450.40M | 71.10M | -6.38M | -39.84M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-24 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-08-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Guggenheim | Buy |
| 2024-09-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-13 | Iniziato | H.C. Wainwright | Neutral |
| 2021-09-02 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-19 | Iniziato | Truist | Buy |
| 2019-10-16 | Iniziato | Mizuho | Buy |
| 2018-11-19 | Iniziato | Leerink Partners | Outperform |
| 2018-10-08 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-04-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | Iniziato | Jefferies | Buy |
| 2017-05-30 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Assembly Biosciences Inc Borsa (ASMB) Ultime notizie
Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks
Assembly Biosciences closes $115 million stock offering By Investing.com - Investing.com Australia
Assembly Biosciences closes $115 million stock offering - Investing.com
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
Assembly Biosciences (ASMB) completes $115M stock and pre-funded warrant sale - Stock Titan
Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan
Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)BPI Bull Correction - Newser
Assembly Biosciences prices $100M equity offering - MSN
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm
Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC - TradingView
Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus
Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan
Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK
Assembly Biosciences Expands ABI-6250 Clinical Development to Target Cholestatic Liver Diseases Including PBC and PSC - Minichart
Assembly Biosciences expands ABI-6250 development to liver diseases By Investing.com - Investing.com Nigeria
Assembly Biosciences expands ABI-6250 development to liver diseases - Investing.com UK
Assembly Biosciences prices $100 million stock offering at $26.50 By Investing.com - Investing.com South Africa
Assembly Biosciences prices $100 million offering - The Pharma Letter
Assembly Biosciences Shares Up Amid Expansion of ABI-6250 Drug Development - Moomoo
Assembly Biosciences stock surges on PBC and PSC expansion plan By Investing.com - Investing.com Australia
Assembly Biosciences stock surges on PBC and PSC expansion plan - Investing.com
Assembly Biosciences Expands ABI-6250 Liver Disease Program - TipRanks
Assembly Biosciences Prices $100 Million Offering - Moomoo
Assembly Bio (NASDAQ: ASMB) plans Phase 2 ABI-6250 trials in HDV, PBC and PSC - Stock Titan
Assembly Biosciences Plans Phase 2 Study of ABI-6250 in Cholestatic Liver Diseases PBC and PSC to Begin in Q1 2027 - Quiver Quantitative
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases - The Manila Times
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - marketscreener.com
Biotech Assembly Bio prices $100M sale to fund viral, liver drug work - Stock Titan
Experimental liver drug ABI-6250 heads to Phase 2 tests in PBC and PSC - Stock Titan
Crude Oil Edges Higher; US Consumer Sentiment Falls In May - Sahm
Trading Systems Reacting to (ASMB) Volatility - Stock Traders Daily
Assembly Biosciences, Inc.Common Stock (ASMB) Stock Price, News, Quote & History - FinancialContent
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference - Yahoo Finance
Assembly Biosciences Shares Caution As Healthcare Growth Expectations Fade - Kalkine Media
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts - simplywall.st
Assembly Biosciences to present HDV drug data at EASL congress - Investing.com
Assembly Biosciences to present HDV drug data at EASL congress By Investing.com - Investing.com Australia
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 - The Manila Times
Assembly Biosciences to Present Topline Clinical Data on ABI-6250, a Novel Oral Hepatitis D Virus Entry Inhibitor, at EASL Congress 2026 - Quiver Quantitative
Oral hepatitis D entry inhibitor brings Phase 1a data to Barcelona - Stock Titan
MarketsMedicine Hat News - FinancialContent
Paradigm entities and Dr. Asefaw report holdings in Assembly Biosciences (ASMB) - Stock Titan
Analysts Have Lowered Expectations For Assembly Biosciences, Inc. (NASDAQ:ASMB) After Its Latest Results - simplywall.st
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference - Weekly Voice
Biotech Assembly Bio to speak at BofA 2026 Global Health Care Conference - Stock Titan
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely - Yahoo Finance
Guggenheim Maintains Assembly Biosciences(ASMB.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Assembly Biosciences 1Q Loss/Shr 54c >ASMB - Moomoo
How Assembly Bio (ASMB) benefits from the shifts in its industry (-1.37%) 2026-05-08SuperTrend - Newser
Assembly Biosciences (ASMB) reports Q1 loss, misses revenue estimates - MSN
Assembly Biosciences Inc Azioni (ASMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):